TICKERNERD
Menu
ELABELABHealthcare · Biotechnology

ELAB Stock Forecast: PMGC Holdings, Inc. Price Predictions for 2026-2027

Last close, 15 Sept 2026
$4.82
+4.33% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 14 Sept 2026 — in the weakest quartile.

Market cap
$3.7M
Ticker Nerd rank
3 / 100
Median analyst target
—
Analysts covering
—
Revenue$1.3M
Operating income−$3.8M
Net income−$2.9M
Free cash flow−$2.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.6%
1M
−47.0%
YTD
−98.6%
1Y
−99.7%
From 52W high
−99.8%
From 52W low
+6.6%
$5
$2,167
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELAB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PMGC Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
3 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Accruals
36
Revisions
25
Momentum
18
Growth
3
Issuance
2
Quality
0
Volatility
0
Value
0

Size (97): Smaller than most of the companies we track.

Value (0): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELAB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELAB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$500$1,000$1,500Oct 25Jan 26Apr 26Jul 26ELAB

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELAB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ELAB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Sept 2026, PMGC Holdings, Inc. returned −99.7% against +15.9% for the S&P 500, dividends included.

ELAB vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26ELABS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELAB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

PMGC Holdings, Inc. (ELAB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
1.5×

Cheaper than 61% of US stocks

Price / book
0.2×

Cheaper than 90% of US stocks

EV / EBITDA
0.1×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
91.6%

Higher than 92% of US stocks

Earnings growth (YoY)
—
Gross margin
29.5%

Higher than 33% of US stocks

Operating margin
−290.0%

Higher than 9% of US stocks

Net margin
31.4%

Higher than 90% of US stocks

Returns & dividend
Return on equity
−105.2%

Higher than 13% of US stocks

Return on assets
−33.0%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

PMGC Holdings, Inc. (ELAB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PMGC Holdings, Inc. has a market value of $3.7M and an enterprise value of −$1.1M.

  • Revenue in the twelve months to 30 June 2026: $2.6M. The latest quarter grew 91.6% year on year.

  • Net income over the same four quarters: −$13.5M, a −523.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$9.0M.

  • PMGC Holdings, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 4.5M.

  • Trailing P/E: 0.0×.

  • PMGC Holdings, Inc. employs 32 people — $81K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

ELAB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ELABPMGC Holdings, Inc.$3.7M
3
REVBRevelation Biosciences, Inc.$3.7M
7
BRTXBioRestorative Therapies, Inc.$3.7M
8
XRTXXORTX Therapeutics, Inc.$3.8M
13
CVKDCadrenal Therapeutics, Inc.$3.8M
34
TCRTAlaunos Therapeutics, Inc.$3.6M
29
MBIOMustang Bio, Inc.$3.9M
13

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PMGC Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELAB news & analysis

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications

GlobeNewsWire · 1 Sept 2026positive

NorthStrive Biosciences announced an expansion of its AI-driven drug discovery program in collaboration with Yuva Biosciences, advancing four novel AI-discovered compounds toward lead nomination for potential cardiac disease and obesity therapeutic applications.

Why it matters — ELAB watchers may see this as relevant given the company's connection to NorthStrive or the AI-based drug discovery space, and the advancement of four compounds signals continued pipeline progress.

PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio

GlobeNewsWire · 26 Aug 2026neutral

PMGC Holdings terminated a previously announced acquisition letter of intent following its due diligence review, while reaffirming its disciplined M&A strategy and expanding its investment across its aerospace and defense manufacturing portfolio.

Why it matters — ELAB watchers would care because the company is signaling a cautious, disciplined approach to acquisitions while continuing to grow its aerospace and defense investments.

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss

GlobeNewsWire · 25 Aug 2026positive

PMGC Holdings announced it has entered into a term sheet with Orbit2Orbit for its NorthStrive Biosciences arm to launch a spaceflight study of its myostatin and activin A assets, EL-22 and EL-32, targeting microgravity-induced muscle loss. The announcement was reported by GlobeNewsWire.

Why it matters — ELAB watchers would care because this new study could extend the company's drug development pipeline into a novel spaceflight application for muscle-wasting conditions.

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

GlobeNewsWire · 21 Aug 2026neutral

NorthStrive Biosciences announced it has filed two U.S. patent applications targeting microgravity-induced muscle loss during long-duration spaceflight, as reported by GlobeNewsWire.

Why it matters — A watcher of ELAB would care because this patent filing could relate to the company's broader biosciences and space-health initiatives, potentially expanding its intellectual property and market focus.

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

GlobeNewsWire · 19 Aug 2026neutral

PMGC Holdings Inc. (NASDAQ: ELAB) announced it will effect a 1-for-10 reverse stock split of its issued, outstanding, and authorized common stock, effective at 12:00 am Eastern time on August 21, 2026.

Why it matters — ELAB watchers would care because the reverse stock split will consolidate the company's share count and raise the per-share price, altering the stock's market structure.

FAQ

Frequently asked questions about ELAB stock

How does Ticker Nerd's model rank ELAB?

As at 14 Sept 2026, PMGC Holdings, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the ELAB stock forecast for 2030?

No analyst covering PMGC Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELAB are extrapolating price history, which says nothing about the business.

How has ELAB stock performed over the past year?

PMGC Holdings, Inc. returned -99.7% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PMGC Holdings, Inc. do?

PMGC Holdings Inc. is a diversified holding company that focuses on building a portfolio of operating businesses across manufacturing, biosciences, packaging, and precision engineering.

What is the latest news on ELAB?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications". NorthStrive Biosciences announced an expansion of its AI-driven drug discovery program in collaboration with Yuva Biosciences, advancing four novel AI-discovered compounds toward lead nomination for potential cardiac disease and obesity therapeutic applications.

Company

About PMGC Holdings, Inc.

PMGC Holdings Inc. is a diversified holding company that focuses on building a portfolio of operating businesses across manufacturing, biosciences, packaging, and precision engineering. PMGC Holdings Inc. serves as a parent company for subsidiaries involved in specialized industrial and technology-driven markets, including aerospace and defense supply chains, industrial packaging, and high-tolerance machining services. Its biosciences activities center on aesthetic and therapeutic products, supported by research and development in skincare-related and probiotic-based applications. The company also operates investment and capital management activities as part of its broader business structure. Based in Newport Beach, California, PMGC Holdings Inc. plays a role in connecting niche operating companies under one platform, combining manufacturing capabilities with healthcare-oriented innovation.

CEO Mr. Graydon Bensler C.F.A. · 32 employees · United States · https://pmgcholdings.com